Patents by Inventor Ali Khodayari

Ali Khodayari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12234463
    Abstract: Described herein are engineered cells including ones having synthetic methylotrophy which include an NADH-dependent enzyme capable of converting G3P to 3PG (e.g., B. methanolicus gapN) and/or fructose-1,6-bisphosphatase, along with hexulose-6-phosphate synthase, 6-phospho-3-hexuloisomerase, a phosphoketolase, or a combination thereof. Engineered cells of the disclosure beneficially maintain adequate pool sizes of phosphorylated C3 and/or C4 compounds, and/or provide increased levels of NADPH. As such, the modifications allow for the generation of C6 compounds from C1 (e.g., a methanol feedstod) and C5 compounds, the regeneration of C5 compounds from C6 compounds by carbon rearrangement, and an improved balance between regeneration of C5 compounds and lower glycolysis. In turn, this allows the engineered microorganism to generate sufficient quantities of metabolic precursors (e.g.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: February 25, 2025
    Assignee: Genomatica, Inc.
    Inventors: Harish Nagarajan, Tae Hoon Yang, Ali Khodayari
  • Publication number: 20220291211
    Abstract: Described herein are devices and methods for improved detection and quantitation of biomolecules. Devices and methods may include a microfluidic biosensing platform for measuring electrical impedance changes in the presence of target analytes from sinusoidal input voltages to improve the sensitivity of immunoassays. In one embodiment, the described devices and methods may provide a point-of-care immunoassay platform for quantitative diagnostics using signal-enhancing microparticles to improve sensitivity and the limit-of-detection.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 15, 2022
    Inventors: Jungkyu KIM, Ali Khodayari BAVIL
  • Publication number: 20220177895
    Abstract: Described herein are engineered cells including ones having synthetic methylotrophy which include an NADH-dependent enzyme capable of converting G3P to 3PG (e.g., B. methanolicus gapN) and/or fructose-1,6-bisphosphatase, along with hexulose-6-phosphate synthase, 6-phospho-3-hexuloisomerase, a phosphoketolase, or a combination thereof. Engineered cells of the disclosure beneficially maintain adequate pool sizes of phosphorylated C3 and/or C4 compounds, and/or provide increased levels of NADPH. As such, the modifications allow for the generation of C6 compounds from C1 (e.g., a methanol feedstod) and C5 compounds, the regeneration of C5 compounds from C6 compounds by carbon rearrangement, and an improved balance between regeneration of C5 compounds and lower glycolysis. In turn, this allows the engineered microorganism to generate sufficient quantities of metabolic precursors (e.g.
    Type: Application
    Filed: June 26, 2019
    Publication date: June 9, 2022
    Inventors: Harish Nagarajan, Tae Hoon Yang, Ali Khodayari